After sluggish start in mRNA, Sanofi sets out stall for vaccines future

1 December 2021

French pharma major Sanofi (Euronext: SAN) is hosting a vaccines investor event which emphasizes the company’s ambitions and optimistic forecasts for the therapy area.

Sanofi is pursuing what it calls a “Play to Win” strategy to generate new growth opportunities and to build “an industry-leading vaccines pipeline.”

The firm has guided that it expects mid-to-high single-digit growth for its vaccines business for 2021, with sustained growth driven by its four core franchises of influenza, meningitis, PPH3 & boosters.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK